Chengdu Yuheng Investment

Zhou Houcheng, founder of Sichuan New Green Pharmaceutical, is the core principal driving the investment network. He is supported by family member Zhou Qiaomin and business partner Chen Chunchao, both of whom hold significant roles across the group entities. No external CIO or dedicated investment head has been publicly identified, suggesting Zhou retains final authority over capital allocation.

The investment firm functions as the investment vehicle for wealth generated by Zhou Houcheng's pharmaceutical operations. There is no known structural separation between the two — key executives serve across both the pharmaceutical manufacturing side and the investment entity. The investment firm's real asset holdings include multiple TCM production bases tied directly to New Green Pharmaceutical's supply chain (public record).

Based on the disclosed asset base — which consists entirely of direct operating subsidiaries and physical production bases — the firm appears to allocate exclusively to direct deals and wholly-owned subsidiaries. No track record of LP commitments to external funds has been publicly identified.

Healthcare services, real estate, and industrial production form the core allocation. The healthcare focus is specifically anchored in traditional Chinese medicine manufacturing and distribution. Real estate holdings support pharmaceutical operations, and a mobile smart-pharmacy fleet bridges healthcare services with industrial technology.

Philanthropic activity is visible through a donation program directed at Henan University of Chinese Medicine. The program supports TCM education and is consistent with the firm's healthcare-focused asset base, though no standalone foundation structure has been publicly disclosed.

There is no public record of the firm participating in co-investments alongside external general partners. The group's disclosed holdings consist entirely of proprietary operating subsidiaries and physical assets, suggesting a preference for wholly-owned control rather than minority-position club deals.

The wealth originates from Zhou Houcheng's ownership of Sichuan New Green Pharmaceutical, a scaled manufacturer of traditional Chinese medicine products. The firm's investable capital base is tied to pharmaceutical operating profits rather than a technology exit or diversified holding company.